farnesol has been researched along with Multiple Myeloma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KS; Kim, C; Kim, SH; Lee, JH; Sethi, G | 1 |
| Iguchi, T; Ikeda, Y; Kizaki, M; Miyakawa, Y; Yamamoto, K | 1 |
| Croucher, PI; Helfrich, MH; Rogers, MJ; Russell, RG; Shipman, CM | 1 |
3 other study(ies) available for farnesol and Multiple Myeloma
| Article | Year |
|---|---|
Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Farnesol; Female; Humans; Mice; Multiple Myeloma; Pyrazines; Random Allocation; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2015 |
Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.
Topics: Apoptosis; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Imidazoles; Interleukin-6; MAP Kinase Signaling System; Mevalonic Acid; Multiple Myeloma; Phosphorylation; Protein Kinases; S Phase; Signal Transduction; Stromal Cells | 2003 |
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Lovastatin; Mevalonic Acid; Multiple Myeloma; Protein Prenylation; Tumor Cells, Cultured | 1998 |